Raphin1

• Description :

  Raphin1 is an orally bioavailable, selective inhibitor of the regulatory phosphatase PPP1R15B (R15B) . Raphin1 binds strongly to the R15B-PP1c holophosphatase (Kd=33 nM), and shows ~30-fold selective in binding R15B-PP1c over R15A-PP1c. Raphin1 crosses the blood-brain barrier, and reduces organismal and molecular deficits in a mouse model of a protein misfolding disease[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Phosphatase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/raphin1.html

• Purity :

  99.75

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  N=C(N/N=C/C1=CC=CC(Cl)=C1Cl)N

• Molecular Formula :

  C8H8Cl2N4

• Molecular Weight :

  231.08

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Krzyzosiak A, et al. Target-Based Discovery of an Inhibitor of the Regulatory Phosphatase PPP1R15B. Cell. 2018 Aug 23;174 (5) :1216-1228.e19.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Citation 01 :

  Nat Commun. 2024 Aug 9;15 (1) :6810.|bioRxiv. 2024 Feb 5.|Nature. 2023 Sep;621 (7977) :188-195.

• CAS Number :

  [2022961-17-5]